Oruvail Gel and Orugesic Gel (Ketoprofen) - Important Safety Information from Sanofi Aventis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 09/08/2010

 

Problem Or Issue:

Important Safety Information communication from Sanofi Aventis - risk minimisation measures for ketoprofen-containing topical formulations

Important Safety Information - Oruvail 2.5% w/w Gel PA 540/119/4 and Orugesic 2.5% w/w Gel PA 540/118/1 (Ketoprofen)

 


« Back